Skip to main content

Table 4 Effects of losartan, metformin and glibenclamide on systolic blood pressure of DOCA + STZ hypertensive diabetic rats

From: Antihypertensive and antihyperglycemic effects of combinations of losartan with metformin and/or glibenclamide in desoxycorticosterone acetate and streptozotocin-induced hypertensive diabetic rats

Treatment

Initial (mmHg)

Week 1

Week 2

Week 3

Week 4

Week 8

Normal Control

89.67 ± 0.33

88.67 ± 2.73

89.33 ± 3.84

96.33 ± 7.33

97.33 ± 2.85

100.33 ± 2.73

HD Control

90.33 ± 3.18

127.67 ± 1.45*

134.33 ± 0.88*

147.67 ± 4.33*

147.67 ± 5.04*

146.67 ± 3.48*

HD + LOS + MET

93.33 ± 0.33

118.33 ± 1.76*#

126.67 ± 3.53*

130.67 ± 0.33*

120.67 ± 6.39#

115.67 ± 4.91#

HD + LOS + GLB

96.33 ± 0.33

118.67 ± 0.33*#

121.67 ± 1.20*#

128.33 ± 2.03*#

119.33 ± 6.36#

121.67 ± 2.03*#

HD + LOS + MET + GLB

95.00 ± 8.14

116.67 ± 1.76*#

118.33 ± 2.33*#

123.33 ± 0.88*#

111.33 ± 5.93#

112.00 ± 4.93#

  1. All values are expressed as mean ± SEM (n = 5). *P < 0.05 when compared with normal control; #P < 0.05 when compared with hypertensive diabetic control. (HD Control Hypertensive Diabetic Control, HD Hypertensive Diabetic Rats, LOS Losartan, MET Metformin, GLB Glibenclamide)